AbbVie (NYSE:ABBV) announced that its mid-stage study of Botox (onabotulinumtoxinA) for treating essential tremor in the upper limbs achieved its main goal. The research successfully reached its primary goal, showing significant improvements in the tremor disability scale for onabotulinumtoxinA compared to ...